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ABSTRACT

Low-grade serous carcinoma is one of the five major histological types of ovarian
carcinoma associated with a specific biology. We reviewed three cases from our institution to
demonstrate the variable clinical course and provide a brief review on this disease entity.
KEYWORDS: Low-grade serous carcinoma; High-grade serous carcinoma; Ovarian cancer.
INTRODUCTION

In 1996, Burks et al. described a peculiar micropapillary serous tumor.1 Eighteen years
later, the 2014 WHO separated low-grade serous carcinomas (LGSC) from high-grade serous
carcinoma (HGSC) as individual histological type rather than a being just another level in the
grading system. While both serous carcinomas share the same cell lineage (indicated by ubiquitous PAX8 and WT1 expression), this separation was based on distinct oncogenic pathways,
histopathology and clinical behavior.2,3 The mean age of women diagnosed with LGSC is 55
years, which is six years younger than HGSC.4 LGSC account for only 4% of ovarian carcinomas, but LGSC represents the second most common histotype presenting with advanced
disease after HGSC. Still even in the high stage setting, the ratio of LGSC to HGSC is 1:16.5 In
2004, Shih and Kurman proposed the dualistic model of serous carcinogenesis.6 The majority of
LGSC show mutations in KRAS or BRAF mutations and a lower proliferation compared to HGSC.7 TP53 mutations are almost a defining feature for HGSC and should not be seen in LGSC.
Hence, KRAS/BRAF/TP53 mutations are so specific that they can be used diagnostically.8,9 Yet
a diagnosis can often be made with high reproducibility based on simple morphology using the
degree of nuclear atypia in conjunction with architectural patterns and ancillary immune-histochemistry.10 While HGSC are a focus of research,11 there are relatively few studies of LGSC
and no recurrent alterations beyond KRAS and BRAF have been identified.12-14
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LGSC are commonly associated with metachronous or synchronous serous borderline tumors/Atypical Proliferative Serous Tumors (APST). APST display two distinct morphological phenotypes: a hierarchical branching pattern seen in the conventional type (not further
specified) or a micropapillary pattern seen in the micropapillary variant. Seven percent of patients diagnosed with APST may subsequently develop LGSC. A recent study investigating
five paired metachronous APST and LGSC showed that the same KRAS mutation was already
present in three preceding APST, although only in minor subclones by the use of deep/sensitive
sequencing, providing evidence that some metachronous APST and LGSC are clonally related.13 Risk factors for progression to LGSC include APST presenting at higher stage, showing
microinvasion or micropapillary variant.15 The micropapillary variant shows an expression pro-
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file more closely related to LGSC compared to the conventional
variant and could be therefore considered as the noninvasive
precursor of LGSC.16 LGSC are commonly associated with synchronous APST. A diagnosis of LGSC is made if frank invasion
is present. Frank invasion is to be distinguished from microinvasion by a quantitative threshold of an invasive area greater
than 5 mm in extent. The classic histological pattern of invasion
displays micropapillae in non-epithelial lined cleft-like spaces
but alternative patterns, such as macropapillary, solid, glandular
with or without extensive psammomatous calcifications (“psammocarcinoma”), can occur.17 The location of frank invasion can
be variable including sites such as ovary, peritoneum or lymph
nodes.18 Noteworthy, assessment of invasion in the peritoneum
(“invasive implants”) versus noninvasive implants of APST
quality is one of the most challenging decisions to be made in
gynecological pathology.
Chemotherapy administration is constantly refined resulting in increased efficacy for HGSC.19 A series of studies from
MDACC reported that LGSC are only occasionally responding
to chemotherapy and highlight the importance of surgery.20-22
A recent study from a population-based series challenged the
assumption that LGSC usually have a more favorable outcome
than HGSC.23,24 We recently observed a variable clinical course
of women diagnosed with LGSC. To illustrate, we present three
recent cases from our institution. Institution review from Ethics Committee was obtained for a larger review on outcomes of
low-grade serous carcinoma of the ovary.
Case A

A 63-year old woman was followed up since 1995. She
underwent primary optimal debulking surgery; she was staged
as a stage IIIC, well differentiated papillary serous adenocarcinoma of the ovary. On contemporary pathology review the tumor showed 7 mm frank invasion in form of macropapillae in a
background of serous borderline tumor, micropapillary variant
with multiple other foci of microinvasion. Postoperatively she
received adjuvant chemotherapy with six cycles of single agent
cisplatin at 60 mg/m2, she tolerated treatment well and remained
in remission. She recurred nine years later and we managed her
with neoadjuvant chemotherapy, three cycles of Q21carboplatin
at AUC of 5 and Paclitaxel 175 mg/m2 and secondary debulking
procedure. Optimal debulking was achieved, which was followed
with adjuvant chemotherapy with three cycles of Q 21 carboplatin at AUC of 5 and paclitaxel 175 mg/m2 that was tolerated well.
She remained in remission for two years. A second recurrence
in 2006 was managed with two lines of chemotherapy, initially
offered liposomal doxorubicinat 40 mg/m2 every 4 weeks, after
2 cycles this was discontinued due to intolerable side effects. We
subsequently switched her to single agent topotecan at 1.25mg/
m2 for 5 days Q 21 for four cycles. The patient opted out of
follow up and self medicated with dicholoroacetic acid and thalidomide, she remained stable for two years. A third recurrence
presented as bowel obstruction. Following failure of initial conservative management, surgical management with a right hemi-
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colectomy followed with three lines of adjuvant chemotherapy
with single agent gemicitabine at 1 g/m2 every three weeks for
6 cycles, tolerated treatment well but due to progressive disease
she was enrolled in a clinical trial unfortunately she progressed
on the trial she was offered single agent weekly paclitaxel at 80
mg /m2 for 6 cycles. Following another two years in remission,
she presented with a forth recurrence that was managed by excision of a left rectus muscle tumor, retroperitoneal tumor and
partial cystectomy and adjuvant chemotherapy with six cycles of
carboplatin at AUC of 5 and paclitaxel 175 mg/m2, she tolerated
treatment well. Unfortunately she developed progressive disease
that caused her to succumb 18 years after the initial diagnosis.
On pathology review, all her recurrences were classic LGSC retaining minor areas of a macropapillary pattern seen in the initial
case (Figure 1A).
Case B

A 55-year old, initially presented with advanced ovarian cancer and she underwent a total abdominal hysterectomy;
bilateral salpingo oophorectomy and omentectomy for a stage
IIC papillary serous ovarian cancer, optimally debulked, she received six cycles of adjuvant treatment with chemotherapy with
six cycles of Q 21 carboplatin at AUC of 5 and paclitaxel 175
mg/m2, she tolerated treatment well. After five years of remaining in remission she was discharged from the cancer center and
followed up by her family physician. Seven years after the initial treatment she developed a 2 cm swelling in her abdominal
wall, which was followed radiologically. Five years later it was
noted to double in size. A biopsy form this revealed serous carcinoma. She had surgical debulking to microscopic disease and
is currently receiving adjuvant chemotherapy with carboplatin at
AUC of 5 and paclitaxel 175mg/m2 (Figure 1B).
Case C

A 33-year old woman presented with abdominal pain,
weight loss and menstrual irregularities. Medical report from
her home country indicated that she underwent a left salpingooophorectomy and omentectomy and postoperatively adjuvant
chemotherapy for an ovarian tumor. On review at our institution, she presented with increasing abdominal girth, pain and
shortness of breath. A Computerized Topographical (CT) scan
revealed a left sided pleural effusion, free intraperitoneal fluid
and an ill defined right adnexal mass. Cytology from ascitic
fluid revealed metastatic adenocarcinoma of ovarian origin. She
received three cycles of neoadjuvant chemotherapy with three
cycles of carboplatin at AUC of 5 and paclitaxel 175 mg/m2 followed by an interval debulking procedure where microscopic
debulking was achieved. Pathology from the surgical specimen
was reported as LGCS of the ovary (Figure 1C, and 1D). Subsequently, she received six cycles of adjuvant chemotherapy with
six cycles of carboplatin AUC of 5 and paclitaxel 175 mg/m2.
Soon after completion of adjuvant treatment she developed progressive disease and was started on second-line chemotherapy,
liposomal doxorubicin 40 mg/m2 Q28, unfortunately she died
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Figure 1: (A) Low-grade serous carcinoma with typical micropapillary low power architecture on the right and variant pattern on the left:
so called micropapillary inside out pattern. In both pattern papillae are surrounded by non-epithelial lined cleft-like spaces. The nuclei are
monomorphic lacking significant nuclear atypia (case A).
(B) Low-grade serous carcinoma with typical micropapillary low power architecture and abundant psammoma bodies, which are often
seen in low-grade serous carcinoma (so called psammocarcinoma being the extreme variant). The nuclei are monomorphic lacking
significant nuclear atypia (case B).
(C) Low-grade serous carcinoma with typical micropapillary low power architecture and monomorphic nuclei (case C)
(D) TP53 immunohistochemistry on specimen from case C displaying TP53 wild type pattern. This pattern is characterized by a heterogeneous expression of TP53 with variable intensity in 1-70% of tumor nuclei similar to normal fallopian tube (inset). This pattern is distinct
from aberrant TP53 expression seen in high-grade serous carcinomas indicative of underlying TP53 mutation, which is characterized by
either diffuse overexpression (>70% of nuclei displaying strong expression) or complete absence (lack of any expression with positive
internal control from lymphocytes and fibroblasts, not shown).

within eleven months of initial diagnosis and treatment (Table
1).
Case A

Case B

Case C

Age at diagnosis

48

55

33

Stage at diagnosis

IIIC

IIC

IIIC

Time to first recurrence
(months)

113

175

Progression under
adjuvant therapy

Time to from diagnosis
to death (months)

227

Alive with
disease

11

Time to from first
recurrence to death
(months)

114

Alive with
disease

NA

WT1

Diffuse

Diffuse

Diffuse

TP53

Wild type

Wild type

Wild type

P16

Patchy

Patchy

Patchy

ER

Diffuse

Diffuse

Diffuse

PR

Negative

Diffuse

Negative

Table 1: Case characteristics.

DISCUSSION

LGSC has been traditionally viewed as indolent disease
compared to HGSC. In a recent population based series, however, the long-term outcome of patients diagnosed with LGSC
was similar to HGSC.25 What could be the reason for those dif-
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ferences? We illustrated a variable clinical course. Two of our
cases showed a long term survival despite recurrent disease but
the third case showed an aggressive course. Hence, could above
cited studies could have had a selection bias towards indolent
or aggressive cases? Currently, there are no reliable criteria to
assess prognosis of LGSC. Strong/diffuse progesterone receptor
expression has been suggested as favorable prognostic marker
(RR=0.39, 95% confidence interval 0.018-0.86).4 The G12V
KRAS mutation was associated with unfavorable outcome in a
small series.13 Whether these biomarker play out in clinical practice requires further validation.
LGSC is uncommon and only recently established. In
a interobserver reproducibility study of eight pathologists from
European Nordic countries, consistent diagnosis of LGSC was a
major issue.26 The main differential diagnoses are against APST,
endometrioid carcinoma and HGSC. In a large population based
series from Denmark, only 30% of LGSC were confirmed on
review but 12% of LGSC were reclassified to HGSC and 50%
to APST.24 A favorable outcome of LGSC can be seen in cohorts
that are contaminated by misclassified APST. This challenge is
illustrated by our first case. The initial tumor consisted predominantly of APST with foci of frank invasion just exceeding the
5 mm threshold representing an example for a diagnosis of an
LGSC at the lower end of the spectrum. All recurrences of this
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case, however, were bona fida LGSC (Figure 1A). Even if the
initial diagnosis is disputed, the survival from the first recurrence was still greater than nine years. Another diagnostic issue
is illustrated with the third case that showed solid pattern in addition to the typical micropapillary features (Figure 1C). This
solid pattern raised the differential diagnosis of HGSC. HGSC
ubiquitously harbor TP53 mutations and contemporary TP53
immuno-histochemistry serves as a good surrogate for the TP53
mutational statues. There was no evidence for TP53 mutation by
immune-histochemistry (Figure 1D).
Clinical management greatly influences the course of
the disease. The MDACC group has long been advocating for an
aggressive surgical approach, which yields a relative good outcome in their patient series.23 Treatment alternatives are limited.
Chemotherapy can induce stable disease and achieve disease
control, but responses are rare. Similarly, hormonal therapy may
contribute to disease control but response rates are low (9%) and
may depend on the PR receptor status.27 In contrast to breast
cancer, the optimal cut-off for PR expression as prognostic or
predictive marker for LGSC is not established.28 PR expression
is present in most LGSC but only a quarter expresses high levels
of PR and only high level expression is associated with unfavorable outcome.4,29
Inhibitors targeting the key aberrant pathway in LGSC
have entered early clinical trials (e.g. EUDRACT Number: 2013000277-72). Selumetinib, a MEK 1/2 inhibitor, was studied in
a phase 2 trial of 52 women with recurrent LGSC achieving a
complete or partial response rate of 15% and 65% of patients had
stable disease.30 The responses were not related to the mutational
status of KRAS or BRAF raising the question whether other functionally redundant aberrations in the MAPK pathway were present in cases wild type for KRAS or BRAF that responded. It also
suggests that some LGSC with KRAS or BRAF mutation that did
not respond may have additional alterations inducing primary
resistance to MEK inhibitors. Further comprehensive molecular assessment combining different platform (whole genome sequencing, copy number analysis, methylome, micro RNAs) on
contemporarily classified cases with detailed clinical follow up
is required to increase our understanding of this uncommon disease.
We started to manage LGSC differently from HGSC.
In the initial diagnostic setting, we prefer upfront surgery for
LGSC while neoadjuvant chemotherapy is an option for HGSC.
Although there are clinical hints for LGSC (younger age, lower
CA125),31 we push for a tissue based diagnosis preferentially
an omental core biopsy. These biopsies have the advantage that
immune-histochemical markers (panel of PAX8, WT1, TP53,
p16) can be more reliably compared to cell blocks obtained from
ascites.6 Because LGSC has only recently been recognized, we
will see recurrences of what was diagnosed well-differentiated serous carcinoma in the past for the upcoming years. Alert
should be raised if the patients are younger, presents with multiple or late recurrences that do not respond to chemotherapy.
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However, this can overlap with patients with HGSC carrying a
BRCA germline mutation that that acquired resistance to chemotherapy. The decision between recurrence surgery for LGSC
and additional lines of chemotherapy for HGSC may require a
contemporary tissue based diagnosis.
In summary, LGSC is a separate disease entity with
variable clinical outcome. The variable outcome depends on the
biology of individual cases (improved understanding requires
comprehensive molecular characterization beyond MAPK pathway), the clinical management (the relative resistance to chemotherapy leaves aggressive surgery as the primary treatment), and
diagnostic accuracy (to improve diagnostic accuracy, ancillary
tests should be judiciously applied).
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